This clinical trial is focused on studying a condition known as primary premature ejaculation, which is a common sexual issue where ejaculation happens sooner than desired during sexual activity. The study will evaluate a treatment using a medication with the code name BP1.4979. This medication is taken in the form of a tablet and is being compared to a placebo to see how effective it is in improving the condition.
The purpose of the study is to assess the effectiveness and safety of BP1.4979 over a 12-week period. Participants will be randomly assigned to receive either the medication or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure the results are unbiased. Throughout the study, participants will be asked to report on their experiences and any changes they notice in their condition.
The study will involve several visits where participants will provide feedback on their condition, including their control over ejaculation and overall sexual health. This feedback will be collected using various questionnaires and scales to measure changes over time. The goal is to determine if BP1.4979 can significantly improve the symptoms of primary premature ejaculation compared to the placebo.
France 
